The $680m deal includes UCB's brands Keppra, Vimpat, Neupro, Zyrtec, Xyzal, and its Zhuhai manufacturing site, and was made in partnership with Mubadala Investment Co.
The US venture capital firm has made early-stage investments in space, cybersecurity, biotech, nanotech, drones and robotics; recently promoted Chip Whittemore will lead the team.
APSEZ has sealed the deal for $185m in cash, which will help it expand offshore support vessel operations in the Middle East, the Indian subcontinent, Far East Asia and Africa.
Group chief executive officer P. Murlidhar (Murli) Maiya recently discussed the infrastructure debt financing landscape and its scalability with FinanceAsia.